Fulvestrant

October 19, 2020October 19, 2020

Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

News

Signatera, Natera’s personalized test to detect residual signs of cancer in people with solid tumors, will be used in an upcoming Phase 2 trial as a tool to identify patients with ... Read more

September 17, 2020September 17, 2020

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

News

TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose in ... Read more

August 24, 2020August 24, 2020

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

News

The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative ... Read more

March 26, 2020March 26, 2020

Tumor Suppressor Neurofibromin Interacts with Estrogen Receptor, Revealing Potential Combo Breast Cancer Therapy

News

A tumor suppressor protein called neurofibromin, known to block the cancer-inducing Ras pathway, also was found to interact directly with the estrogen receptor (ER) with mutations in this protein leading ... Read more

January 24, 2020February 6, 2020

Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says

News

Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), in ... Read more

October 16, 2019

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. ... Read more

October 4, 2019October 7, 2019

Verzenio-Faslodex Combo Prolongs Survival of Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase ... Read more

September 27, 2019October 16, 2019

Mylan Launches Generic Version of Faslodex Injection in the US

News

The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company ... Read more

August 14, 2019

Eagle Prepares Clinical Trials of New Form of Fulvestrant to Treat ER-positive Breast Cancer

News

Eagle Pharmaceuticals is preparing a pilot study that may pave the way for a pivotal clinical trial evaluating its new formulation of fulvestrant as a treatment for estrogen receptor (ER)-positive breast ... Read more

August 2, 2019

Verzenio-Faslodex Combo Prolongs Survival in Advanced Breast Cancer, Interim Phase 3 Data Show

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis ... Read more